Skip to content

Safety and Feasibility Assessment of Single-Port Robotic-Assisted Radical Gastrectomy for Gastric Cancer(SPORTS-04)

Safety and Feasibility Assessment of Single-Port Robotic-Assisted Radical Gastrectomy for Gastric Cancer(SPORTS-04)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111054
Enrollment
Unknown
Registered
2025-10-24
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric adenocarcinoma

Interventions

Single-Port Robotic-Assisted Gastrectomy for Gastric Cancer:Single-Port Robotic-Assisted Gastrectomy for Gastric Cancer

Sponsors

Army Medical Center of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age 18–75 years. 2.Pathologically confirmed gastric adenocarcinoma by endoscopic biopsy. 3.Clinically staged as endoscopically unresectable T1, or cT2–4a, N–/+, M0 according to the AJCC Cancer Staging Manual, 7th edition. 4.Eligible for radical surgical resection. 5.ECOG performance status of 0 or 1. 6.ASA physical status class I–III. 7.Signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation. 2.Severe psychiatric disorder. 3.Previous upper abdominal surgery. 4.History of gastrectomy, endoscopic submucosal dissection (ESD), or endoscopic mucosal resection (EMR). 5.Preoperative imaging suggesting regional lymph node enlargement or diameter >3 cm. 6.History of other primary malignancies within 5 years, except appropriately treated non-melanoma skin cancer or carcinoma in situ. 7.Prior neoadjuvant chemotherapy or radiotherapy. 8.History of cerebrovascular accident or myocardial infarction within the past 6 months. 9.Systemic corticosteroid use for >1 month within the past 1 month. 10.Requirement for concurrent surgery for other diseases. 11.Emergency surgery due to complications of gastric cancer (e.g., bleeding, obstruction, or perforation). 12.Participation in another interventional clinical trial within the past 3 months. 13.Active severe infectious disease. 14.Severe systemic comorbidities deemed to contraindicate surgery.

Design outcomes

Primary

MeasureTime frame
Technical success rate;The incidence of serious intraoperative complications;

Countries

China

Contacts

Public ContactLi Fan

Army Medical Center of PLA

levinecq@163.com+86 18696539200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026